Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Abstract LB_A22: Advancing personalized therapies for small cell lung cancer: Exploring HER2-targeting antibody-drug conjugates (ADCs) and SLFN11 biomarker insights

Ali H. Ibrahim, Bingnan Zhang, C. Allison Stewart, Alejandra Serrano, Luisa M. Solis, Wei-Lien Wang, Kavya Ramkumar, Robert J. Cardnell, Runsheng Wang, Alberto Duarte, Jr, Lixia Diao, Yuanxin Xi, Jing Wang, Lauren A. Byers, Carl M. Gay

Mol Cancer Ther (2023) 22 (12_Supplement): LB_A22.

https://doi.org/10.1158/1535-7163.TARG-23-LB_A22

Published: 01 December 2023

View articletitled, Abstract LB_A22: Advancing personalized therapies for small cell lung cancer: Exploring HER2-targeting antibody-drug conjugates (ADCs) and SLFN11 biomarker insights

Journal Articles

Abstract P009: A shared nearest neighbors approach for integrated, multi-platform networks and its application to the exploration of multiomics data from early-stage non-small cell lung cancers

Mol Cancer Ther (2021) 20 (12_Supplement): P009.

https://doi.org/10.1158/1535-7163.TARG-21-P009

Published: 01 December 2021

View articletitled, Abstract P009: A shared nearest neighbors approach for integrated, multi-platform networks and its application to the exploration of multiomics data from early-stage non-small cell lung cancers

Journal Articles

Abstract B064: The Aurora kinase A-inhibitor, alisertib, is a potential candidate for combination with immunotherapy in small cell lung cancer

Carminia M. Della Corte, Liz Lauren Ajpacaja, Robert J Cardnell, Carl M Gay, Lixia Diao, Qi Wang, Kavya Ramkumar, Allison C. Stewart, Rebecca B. Kow, Hannah E Stumpf, You-Hong Fan, Jing Wang, John V Heymach, Lauren A. Byers

Mol Cancer Ther (2019) 18 (12_Supplement): B064.

https://doi.org/10.1158/1535-7163.TARG-19-B064

Published: 01 December 2019

View articletitled, Abstract B064: The Aurora kinase A-inhibitor, alisertib, is a potential candidate for combination with immunotherapy in small cell lung cancer

Journal Articles

Abstract B024: Clinical, genomic, and immune landscape of the receptor tyrosine kinase AXL in non-small cell lung cancer

Kavya Ramkumar, Carminia M. Della Corte, Lixia Diao, Robert J. Cardnell, Vali A. Papadimitrakopoulou, John V. Heymach, Jing Wang, Don L. Gibbons, Lauren A. Byers

Mol Cancer Ther (2019) 18 (12_Supplement): B024.

https://doi.org/10.1158/1535-7163.TARG-19-B024

Published: 01 December 2019

View articletitled, Abstract B024: Clinical, genomic, and immune landscape of the receptor tyrosine kinase AXL in non-small cell lung cancer

Journal Articles

Abstract B032: Proteomic analysis reveals alterations in apoptotic signaling machinery in HPV-associated cancers and identifies BRD4 and BCL2 as potential therapeutic targets in HPV-positive HNSCCs

Claudia Heymach, Robert Cardnell, Lixia Diao, Jing Wang, Kwok-Shing Ng, Lauren Byers

Mol Cancer Ther (2019) 18 (12_Supplement): B032.

https://doi.org/10.1158/1535-7163.TARG-19-B032

Published: 01 December 2019

View articletitled, Abstract B032: Proteomic analysis reveals alterations in apoptotic signaling machinery in HPV-associated cancers and identifies BRD4 and BCL2 as potential therapeutic targets in HPV-positive HNSCCs

Journal Articles

Abstract A096: LKB1 deficiency and KEAP1/NRF2 pathway alterations as biomarkers of response for ATR and ATM inhibitors and other inhibitors of DNA damage response (DDR) in NSCLC

Ana Galan-Cobo, Marlese Pisegna, Kavya Ramkumar, Alissa Poteete, Sungnam Cho, Fahao Zhang, You-Hong Fan, Qi Wang, Lixia Diao, Katharina Schlacher, Jing Wang, Lauren A Byers, John V. Heymcach

Mol Cancer Ther (2019) 18 (12_Supplement): A096.

https://doi.org/10.1158/1535-7163.TARG-19-A096

Published: 01 December 2019

View articletitled, Abstract A096: LKB1 deficiency and KEAP1/NRF2 pathway alterations as biomarkers of response for ATR and ATM inhibitors and other inhibitors of DNA damage response (DDR) in NSCLC

Journal Articles

Abstract B101: TrkB (NTRK2) as a potential therapeutic target in NSCLC in combination with EGFR TKIs

Mia E. Hofstad, Daniel R. Gomez, Monique B. Nilsson, Lauren A. Byers, Lixia Diao, Jing Wang, Lerong Li, Pan Tong, John V. Heymach

Mol Cancer Ther (2018) 17 (1_Supplement): B101.

https://doi.org/10.1158/1535-7163.TARG-17-B101

Published: 01 January 2018

View articletitled, Abstract B101: TrkB (NTRK2) as a potential therapeutic target in NSCLC in combination with EGFR TKIs

Journal Articles

A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Tuhina Mazumdar, Lauren A. Byers, Patrick Kwok Shing Ng, Gordon B. Mills, Shaohua Peng, Lixia Diao, You-Hong Fan, Katherine Stemke-Hale, John V. Heymach, Jeffrey N. Myers, Bonnie S. Glisson, Faye M. Johnson

Mol Cancer Ther (2014) 13 (11): 2738–2750.

https://doi.org/10.1158/1535-7163.MCT-13-1090

Published: 03 November 2014

View articletitled, A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Abstract C117: An integrated proteomic analysis of lung adenocarcinomas from The Cancer Genome Atlas (TCGA) reveals potential targets for oncogene-negative tumors.

Lixia Diao, Pan Tong, Jing Wang, You-Hong Fan, Yiling Lu, Wenbin Liu, Carmen Behrens, Ignacio I. Wistuba, John V. Heymach, John N. Weinstein, Gordon B. Mills, Lauren A. Byers

Mol Cancer Ther (2013) 12 (11_Supplement): C117.

https://doi.org/10.1158/1535-7163.TARG-13-C117

Published: 01 November 2013

View articletitled, Abstract C117: An integrated proteomic analysis of lung adenocarcinomas from The Cancer Genome Atlas (TCGA) reveals potential targets for oncogene-negative tumors.

Journal Articles

Abstract A131: Identification of candidate therapeutic targets in mesenchymal head and neck squamous cell carcinoma.

Milena P. Mak, Lixia Diao, Jing Wang, Patrick KS Ng, You-Hong Fan, Michael D. Story, William N. William, John V. Heymach, John N. Weinstein, Kevin R. Coombes, Lauren A. Byers

Mol Cancer Ther (2013) 12 (11_Supplement): A131.

https://doi.org/10.1158/1535-7163.TARG-13-A131

Published: 01 November 2013

View articletitled, Abstract A131: Identification of candidate therapeutic targets in mesenchymal head and neck squamous cell carcinoma.

Journal Articles

Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP

Xuemei Xie, Chandra Bartholomeusz, Ahmed A. Ahmed, Anna Kazansky, Lixia Diao, Keith A. Baggerly, Gabriel N. Hortobagyi, Naoto T. Ueno

Mol Cancer Ther (2013) 12 (6): 1099–1111.

https://doi.org/10.1158/1535-7163.MCT-12-0737

Published: 09 June 2013

View articletitled, Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP

Includes: Supplementary data

Journal Articles

Abstract B156: An epithelial to mesenchymal transition (EMT) gene expression signature predicts resistance to PI3K/Akt pathway inhibitors in non-small cell lung cancer.

Lauren Averett Byers, Jing Wang, Lixia Diao, Luc Girard, Michael Peyton, Kevin R. Coombes, John N. Weinstein, Varsha Gandi, Nancy Krett, Steven T. Rosen, John D. Minna, John V. Heymach

Mol Cancer Ther (2011) 10 (11_Supplement): B156.

https://doi.org/10.1158/1535-7163.TARG-11-B156

Published: 12 November 2011

View articletitled, Abstract B156: An epithelial to mesenchymal transition (EMT) gene expression signature predicts resistance to PI3K/Akt pathway inhibitors in non-small cell lung cancer.

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract LB_A22: Advancing personalized therapies for small cell lung cancer: Exploring HER2-targeting antibody-drug conjugates (ADCs) and SLFN11 biomarker insights

Abstract P009: A shared nearest neighbors approach for integrated, multi-platform networks and its application to the exploration of multiomics data from early-stage non-small cell lung cancers

Abstract B064: The Aurora kinase A-inhibitor, alisertib, is a potential candidate for combination with immunotherapy in small cell lung cancer

Abstract B024: Clinical, genomic, and immune landscape of the receptor tyrosine kinase AXL in non-small cell lung cancer

Abstract B032: Proteomic analysis reveals alterations in apoptotic signaling machinery in HPV-associated cancers and identifies BRD4 and BCL2 as potential therapeutic targets in HPV-positive HNSCCs

Abstract A096: LKB1 deficiency and KEAP1/NRF2 pathway alterations as biomarkers of response for ATR and ATM inhibitors and other inhibitors of DNA damage response (DDR) in NSCLC

Abstract B101: TrkB (NTRK2) as a potential therapeutic target in NSCLC in combination with EGFR TKIs

A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Abstract C117: An integrated proteomic analysis of lung adenocarcinomas from The Cancer Genome Atlas (TCGA) reveals potential targets for oncogene-negative tumors.

Abstract A131: Identification of candidate therapeutic targets in mesenchymal head and neck squamous cell carcinoma.

Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP

Abstract B156: An epithelial to mesenchymal transition (EMT) gene expression signature predicts resistance to PI3K/Akt pathway inhibitors in non-small cell lung cancer.

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only